Report of Two COVID-19 ARDS (CARDS) Cases Who Survived without Intubation and Mechanical Ventilation
Keywords:
COVID-19, ARDS, CARDS, Mechanical Ventilation, Thorax CT-ScanAbstract
The most severe clinical feature of COVID-19 is Acute Respiratory Distress Syndrome (ARDS) which requires intubation and mechanical ventilation and it occurs in approximately 2.3% of cases. About 94% of of these cases end in death. This case series report two confirmed COVID-19 patients who had met criteria of intubation and mechanical ventilation, but not performed to them. Both patients experienced clinical improvement and recovery. Probably this is due to differences of COVID-19 ARDS (CARDS) with typical or classic ARDS. CARDS is divided into two phenotypes of type L (Low Elastance) and type H (High Elastance). These different phenotypic also distinguish subsequent pathophysiology and clinical management. These phenotype can be differentiate by chest CT scan. This case series emphasizes the importance of understanding this phenotype so that clinicians can provide more appropriate treatment management and also availability of CT scans in health facilities that manage COVID -19.References
WHO. Clinical management of severe acute respiratory infection when COVID-19 is suspected. Interim Guidance 13 Maret 2020.
WHO. Coronavirus disease 2019 (COVID019) situation report - 59. Accessed March 20, 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200319-sitrep-59-covid-19.pdf.
Yao W, Wang T, Jiang B, et al. Emergency tracheal intubation in 202 patients with COVID-19 in Wuhan, China: lessons learnt and international recommendations. Brit J Anaesthesia Elsevier. 2020; 11(2):3-4.
Riviello ED, Buregeya E, Twagirumugabe T. Diagnosing acute respiratory distress syndrome in resource limited settings: the Kigali modification of the Berlin definition. Curr Opin Crit Care. 2017;23:18-23.
Meng L, Qiu H, Wan L, et al. Intubation and ventilation amid the COVID-19 outbreak. Anesthesiol. 2020; 16(6):3-8.
Vincent J, Taccone F, et al. Understanding pathways to death in patients with COVID-19. Lancet Respir Med. 2020;3.
Gattinoni L, Chiumello D, Caironi P, et al. COVID-19 pneumonia: different respiratory treatment for different phenotypes? Intensive Care Medicine. 2020;3.
Woods A. COVID-19 not your “typical” ARDS. Lippincott 2020 DIkutip dari https://wwwnursingcentercom/ncblog/april-2020/covid-19-not-your-typical-ards.
Siddiqi H, Mehra M, et al. COVID-19 illness in native and immunosuppressed state. J Heart Lung Transplant. 2020.
Cao X. COVID-19: Immunopathology and its implications for theraphy. Nature Rev Immunol. 2020; 20.
Henderson, Canna S, Schulert G, et al. On the alert for cytokine storm: Immunopathology in COVID-19. Research Gate 2020.
Ye Q, Wang B, Mao J, et al. Cytokine storm in COVID-19 and treatment. Elsevier 2020.
Wenjun W, Xiaoqing L, Sipei W, et al. The definition and risk of cytokine release syndrome-like in 11 COVID-19 infected pneumonia critically ill patients: disease characteristics and retrospective analysis. MedRxiv 2020.
Diamanti A, Rosado M, Pioli C, et al. Cytokine release syndrome in COVID-19 patients, a new scenario for an old concern: the fragile balance between infections and autoimmunity. Int J Mol Sci. 2020;21.
Liu J, Li S, Liu JJ, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. Elsevier. 2020;55.
Yuan J, Zou R, Zeng L, et al. The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients. Inflammation Res. 2020;69.
Marini J, Gattinoni L. Management of COVID-19 respiratory distress. JAMA. 2020 Published online April 24, 2020 doi:101001/jama20206825.
Zhao M. Cytokine storm and immunomudulatory theraphy in COVID-19: role of chloroquine and anti-IL-6 monoclonal antibodies. Elsevier. 2020;20.
Downloads
Published
How to Cite
Issue
Section
License
Copyright
The authors who publish in this journal agree to the following requirements:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. (See The Effect of Open Access)
Privacy Statement
The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.